Qualisure Diagnostics Inc. develops molecular diagnostic tests, including the Thyroid GuidePx®, that classify papillary thyroid cancer into three molecular subtypes using fine-needle aspirate samples. This technology enables oncologists to tailor treatment strategies based on the aggressiveness of the cancer, improving patient outcomes and reducing unnecessary healthcare costs.
Funding
$361.3K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Papillary thyroid cancer treatment strategies are often uniform despite varying degrees of aggressiveness, potentially leading to overtreatment for some patients and suboptimal approaches for others. Current diagnostic methods may not accurately classify the cancer's molecular subtype, hindering personalized treatment plans.
Solution
Qualisure Diagnostics provides molecular diagnostic tests, including Thyroid GuidePx®, that classify papillary thyroid cancer into three distinct molecular subtypes using fine-needle aspirate samples. By identifying the molecular subtype, the test enables oncologists to tailor treatment strategies based on the aggressiveness of the cancer. This personalized approach helps to avoid unnecessary treatments for patients with indolent tumors while ensuring aggressive cancers receive the most appropriate intervention. The test results provide clinicians with insights into the tumor's biology, allowing for more informed decisions regarding surgical extent, radioactive iodine therapy, and long-term monitoring. The company leverages next-generation sequencing and machine learning to analyze gene expression patterns and classify tumors into subtypes with differing recurrence risks.
Target Audience
The primary target audience includes oncologists, endocrinologists, and pathologists involved in the diagnosis and treatment of papillary thyroid cancer, as well as patients seeking personalized treatment options.
Features
- Molecular classification of papillary thyroid cancer into three subtypes (Type 1, Type 2, and Type 3) based on gene expression analysis
- Utilizes fine-needle aspirate samples for minimally invasive testing
- Provides a risk score indicating the likelihood of cancer recurrence
- Supports personalized treatment decisions, including surgery and radioactive iodine therapy
- Employs next-generation sequencing (NGS) to analyze gene expression
- Incorporates machine learning algorithms to improve classification accuracy
- Offers prognostic information to guide long-term monitoring strategies